Navigation Links
Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
Date:11/18/2010

NEW YORK, Nov. 18, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biosimilars (Follow-on biologics) Market: An Analysis

http://www.reportlinker.com/p0330557/Global-Biosimilars-Follow-on-biologics-Market-An-Analysis.html

Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S. will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

The report titled "Global Biosimilars (Follow-on biologics) Market: An Analysis" covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

1. Global Biopharmaceutical Market

2. Global Biosimilars Market

2.1 Overview

2.2 Market Size

2.3 Geographical Segmentation

2.4 Currently Marketed Biosimilars

2.4.1 Erythropoietin

2.4.2 Human Growth Hormone

2.4.3 Filgrastim

3. Market Drivers

3.1 Rising Healthcare Costs

3.2 Large Number of Blockbuster Biologics Slated for Patent Expiry

3.3 Leading Generics Players Spearheading Development

3.4 Rise in Ageing Population

3.5 Cost Effective Option for Pharmaceutical Companies

4. Market Constraints

4.1 Regulatory Restrictions and Hurdles

4.2 High Development Costs 24

4.3 Manufacturing Complexities

5. Opportunities

5.1 Burgeoning Indian and Chinese Market

5.2 Monoclonal Antibodies- Fastest Growing segment

6. Market Outlook

7. Major Players

7.1 Teva Pharmaceuticals Industries Ltd.

7.1.1 Business Description

7.1.2 Business Strategies

7.2 Biocon

7.2.1 Business Description

7.2.2 Business Strategies

7.3 Hospira Inc.

7.3.1 Business Description

7.3.2 Business Strategies

Charts and FiguresBiopharmaceutical Value Chain

Global Biopharmaceutical Market (2004-2009)

Global Biopharmaceutical Market by Product (2009)

Categories of Biosimilars Market

Biosimilars Development Process

Difference between Small Molecule Generics and Biosimilars

Global Biosimilar Market Revenue (2008-2014F)

Global Biosimilars Market by Product (2009)

Global Market Potential for Biosimilars in Different Categories (2009)

Major Blockbuster biologics whose patents will expire from 2012- 2019

Marketed Biosimilars by Product Group

Total Healthcare Expenditure Per Capita in Selected Developed Countries (2008)

Real Annual Growth in per Capita Health Spending (%): 2000-2008

Potential Market Potential for Biosimilars

Leading Players in Biosimilars market and Products in Pipeline

Ageing Population Worldwide (age>65) 2005-2015F

Cost Comparison of Biosimilars and Innovator Biologics

Biosimilar Approval in EU

Indian Biosimilars Market Revenue (2008-2012F)

India's Biosimilar Market Breakdown (2009)

Potential Global Market for Biosimilars (2008-2015)

Number of Biologics Scheduled to Go-off Patent (2008-2015)

Annual Revenues of Teva Pharmaceuticals (2005-2009)

Annual Revenues of Biocon (FY 06-FY 10)

Annual Revenues of Hospira Inc. (2009)

To order this report:Biotechnology Industry: Global Biosimilars (Follow-on biologics) Market: An Analysis

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805) 652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS
2. Reportlinker Adds Global HPLC Systems & Accessories Industry
3. Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry
4. Reportlinker Adds Global Freeze Drying Equipment Industry
5. Reportlinker Adds Global Surgical Incision Closures Industry
6. Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
7. Reportlinker Adds Global Uro-Gynecological Surgical Devices Industry
8. Reportlinker Adds Global Sterilization Systems & Equipment Industry
9. Reportlinker Adds Global Breast Pumps Industry
10. Reportlinker Adds Healthcare Reform: 2010 Medical Device Industry Perceptions Survey
11. Reportlinker Adds Global Nutraceuticals Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):